Related Experiment Video
Updated: Aug 29, 2025
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Applications of CRISPR/Cas technology against drug-resistant lung cancers: an update
Mayank Chaudhary1, Pooja Sharma1, Tapan Kumar Mukherjee2
1Department of Biotechnology, Maharishi Markandeshwar (Deemed to Be University), Mullana, Ambala, Haryana, 133207, India.
Abstract:
Out of all the cancer types, the most prevalent one is lung cancer. Multiple genes and signaling pathways play role in the progression of lung cancer. Considering the wider prevalence and fatality of lung cancer it has become the focus of current cancer research. Though currently used approaches have shown positive results against lung cancer but success against non-small cell lung cancer (NSCLC) still looms as an enigma for the entire research fraternity. The development of resistance against inhibitors within a short span is one of the reasons responsible for the failure and relapse of lung cancer. Under these prevailing conditions genome/gene-editing technology using clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR associated proteins (Cas), popularly known as CRISPR/Cas technology offers a convenient and flexible method for inducing precise changes within the lung cancer cell. Additionally, CRISPR-barcoding and CRISPR knockout screens at the genome-wide level can help in the functional investigation of specific mutations and identification of novel cancer drivers respectively. Several variants of the CRISPR/Cas system are being developed to limit off-targeting with enhanced precision. The present review article updates the usefulness of CRISPR/Cas technology against various types of lung cancers.
Insights
Lung cancer is a prevalent disease. CRISPR/Cas gene editing offers precise genome modification for lung cancer research and potential therapeutic strategies, especially for non-small cell lung cancer (NSCLC).
Area of Science:
- Oncology
- Genetics
- Biotechnology
Background:
- Lung cancer, particularly non-small cell lung cancer (NSCLC), remains a significant global health challenge with limited treatment efficacy due to acquired resistance.
- Current therapeutic strategies face challenges in overcoming drug resistance and achieving long-term remission in lung cancer patients.
Approach:
- Genome/gene-editing technology utilizing clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated proteins (Cas), known as CRISPR/Cas technology, provides a precise method for modifying lung cancer cells.
- CRISPR-barcoding and genome-wide CRISPR knockout screens facilitate functional investigation of mutations and identification of novel cancer drivers.
- Advancements in CRISPR/Cas system variants aim to enhance precision and minimize off-target effects for improved safety and efficacy.
Key Points:
- CRISPR/Cas technology enables targeted genetic modifications within lung cancer cells, offering new avenues for research.
- CRISPR-based screening tools are instrumental in uncovering genetic vulnerabilities and mechanisms of resistance in lung cancer.
- The adaptability of CRISPR/Cas systems supports the development of innovative therapeutic strategies against lung cancer.
Conclusions:
- CRISPR/Cas technology presents a powerful and versatile tool for advancing lung cancer research and potentially developing novel treatments.
- This review highlights the significant potential of CRISPR/Cas applications in understanding and combating various forms of lung cancer, including challenging NSCLC cases.
Related Concept Videos
01:59CRISPR
01:28CRISPR/Cas9 Genome Editing
02:53CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...